Company profile
Barinthus Biotherapeutics plc
NASDAQ: BRNS · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
39DFH 40DQ 56GM 1SS 35
v0.1 · 65/100 weight · provisional
↑ filing timeliness, balance-sheet leverage · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$66.4M
Employees
14
as of 2026-08-23
Market cap
$24.6M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$66.4M-$66.4M2025
Operating income-$70.6M-$70.6M2025
Total assets$98.2M$98.2M2025
Liabilities$23.9M$23.9M2025
Equity$74.2M$74.2M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
License100%
By geography
Not disclosed.
The read
What is Barinthus Biotherapeutics plc’s revenue?
Barinthus Biotherapeutics plc booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Defence Therapeutics Inc.——Resverlogix Corp.——EOM Pharmaceuticals Holdings, Inc.——Rein Therapeutics Inc.36DOcumetics Technology Corp.——KALA BIO, Inc.30DNeighbors
Montgomery →Key facts
CEOWilliam James Enright
SectorHealthcare
IndustryBiotechnology
HeadquartersGermantown, MD
ExchangeNASDAQ: BRNS
Employees14
IPO date2021-04-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.